Institutional investors purchased a net $824.9 thousand shares of NLNK during the quarter ended September 2016. This may signal that the smart money is gaining interest in this company as the 47.55% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CANDRIAM BELGIUM SA Bought 115.0 Thousand shares of NewLink Genetics Corp